Group 1 - The first non-surgical targeted drug for treating PFIC, "Bai Er Wei" (generic name: Odevixibat capsules), has been officially launched in China, marking a significant breakthrough in the accessibility of treatment options for PFIC patients [1] - PFIC is a rare genetic disease with an incidence rate of (1-2)/100,000, typically manifesting in newborns or infants under one year old [1] - Odevixibat is the first and only approved non-surgical targeted drug for PFIC in China, which has been included in the domestic and overseas special drug directories of several provinces [1] Group 2 - JD Health's CEO, Jin Enlin, has resigned for family reasons, effective September 29, with a swift appointment of Cao Dong as the new CEO, indicating the company's efficient management response [2] - The resignation of key executives may raise short-term concerns regarding management stability, but the prompt succession plan aims to maintain market confidence [2] Group 3 - Nohui Health, known as the "first stock in cancer early screening," faces delisting risks after being suspended from trading for 18 months due to a short-selling report alleging inflated sales revenue [3] - The company's auditor, Deloitte, refused to endorse its financial statements, leading to the trading suspension, which could severely impact its future business expansion and fundraising efforts [3] Group 4 - Aimeike's subsidiary has received approval for two minoxidil topical solutions (2% and 5%) from the National Medical Products Administration, expanding its product offerings in the hair loss treatment sector [4] - The introduction of these products is expected to create new revenue growth opportunities for Aimeike and enhance its competitive position in the market [4] - This development reflects Aimeike's strength in research and product innovation, which may boost investor confidence and drive stock price appreciation [4]

Core Points - Huatai Fund Management Co., Ltd. announced an adjustment in the valuation of certain funds under its management, specifically regarding the stock of Nohow Health (stock code: 6606.HK) [1] - The valuation adjustment will take effect from September 26, 2025, with the stock being valued at HKD 0.01 per share [1]

（责任编辑：康博） 公告称，创金合信基金管理有限公司经与基金托管人协商一致，自2025年9月26日起，对我司旗下 证券投资基金持有的"诺辉健康（证券代码：6606.HK）"按照0.01港元/股进行估值。 中国经济网北京9月29日讯 近日，创金合信基金管理有限公司发布关于公司旗下部分基金估值调整 情况的公告。 ...

Group 1 - The core point of the announcement is that Xingyin Fund Management Co., Ltd. has decided to adjust the valuation method for its holdings in "Nohow Health" stock, effective from September 26, 2025 [1] - The valuation for the "Nohow Health" stock (stock code: 6606.HK) held by the Xingyin CSI Hong Kong Stock Connect Technology ETF (fund code: 513560) will be set at HKD 0.01 per share [1]

根据《中国证券监督管理委员会关于证券投资基金估值业务的指导意见》（中国证券监督管理委员会公 告[2017]13号）的相关规定，经与基金托管人协商一致，兴银基金管理有限责任公司（以下简称"本公 司"）自2025年9月26日起，决定对兴银中证港股通科技交易型开放式指数证券投资基金（基金代码： 513560）所持有的"诺辉健康"（证券代码：6606.HK）按照0.01港元/股进行估值。 待上述股票体现出活跃市场交易特征后，将恢复为采用当日收盘价格进行估值，届时将不再另行公告。 敬请投资者予以关注。 投资者可通过以下途径咨询有关详情： 本公司网站：www.hffunds.cn 客户服务电话：40000-96326 风险提示：本公司承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基金一定盈利，也 不保证最低收益。基金的过往业绩并不预示其未来表现。投资者投资于本公司管理的基金时应认真阅读 《基金合同》《招募说明书》等法律文件，并注意投资风险。 特此公告。 兴银基金管理有限责任公司 ■ 2.与分红相关的其他信息 ■ 3.其他需要提示的事项 （1）权益登记日申请申购或转换转入的基金份额不享有本次分红权益，权益登记日 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 諾輝健康 | | | | | | 呈交日期: | 2025年9月3日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 06606 | 說明 | 普通股 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.00005 | USD | | 50,000 | | 增加 / 減少 (-) | | ...

Group 1 - The company, Nohow Health (06606), received a letter from the Stock Exchange on August 12, 2025, outlining additional resumption guidance [1] - The guidance includes the removal of the liquidator's appointment and the requirement to comply with listing rules 3.10(1), 3.25, 3.27A, and 13.92 [1] - A hearing regarding the liquidation petition is scheduled for November 14, 2025, at 10:00 AM (Cayman time) in the Grand Court [1]

Core Viewpoint - Nohow Health (06606) has received additional resumption guidance from the Stock Exchange, indicating steps towards lifting the appointment of liquidators and compliance with specific listing rules [1] Group 1 - The company received a letter from the Stock Exchange on August 12, 2025, outlining additional resumption guidance [1] - The guidance includes the removal of the liquidator's appointment and the need to comply with listing rules 3.10(1), 3.25, 3.27A, and 13.92 [1] - A hearing regarding the liquidation application is scheduled for November 14, 2025, at 10:00 AM (Cayman time) in the Grand Court [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本公告全部或任何部分內容所產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 諾輝健康 （已 委 任 共 同 臨 時 清 盤 人） （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） (股 份 代 號：6606) 額外復牌指引 及 有關清盤呈請聆訊之最新消息 本 公 告 由 諾 輝 健 康（「本公司」或「公 司」，連 同 其 附 屬 公 司 及 合 併 聯 屬 實 體，統 稱「本集團」或「集 團」）根 據 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）證 券 上 市 規 則（「上市規則」）第13.09(2)(a)條及第13.24A條，及 證 券 及 期 貨 條 例 （香 港 法 例 第571章）第XIVA部 項 下 之 內 幕 消 息 條 文（定 義 見 上 市 規 則）而 作 出。 額外復牌指引 茲提述(i)本公司日期為2024年5月28日的公告，內容有關聯交所復牌指引； (ii)本公司日期為 ...

诺辉健康(06606)发布公告，孔江南已提出辞任独立非执行董事、董事会薪酬委员会主席、董事会提名 委员会成员，以及公司独立特别委员会成员，自2025年8月8日起生效，以投放更多时间于其他事务及支 持公司有序过渡。 此外，继续停牌。 ...